ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
ARTBIO, 3B Pharmaceuticals | November 14, 2024
Emanuele Ostuni, PhD
Founding CEO
The ARTBIO Approach: Patients at the Core
Radioligand therapy (RLT) has offered a promising new approach for cancer treatment. While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients.
The ARTBIO approach is holistic. It is underpinned by a deep understanding of cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
Our patient-centric approach rests on four pillars:
A Differentiated Pipeline
We are identifying specific combinations of targets and drug molecules best suited for ART. Our ARTs have high affinity and selectivity in order to effectively kill tumors while sparing healthy tissues.
Currently, ARTBIO has four pipeline programs with many more in development:- Our lead program AB001 has entered first in human studies.
- Three additional targets (ABA, ABB, and ABC) remain undisclosed.
- Our lead program AB001 has entered first in human studies.
- Three additional targets (ABA, ABB, and ABC) remain undisclosed.
Programs
Indication
Discovery
Lead Optimization
Phase 0
Clinical Stage (Phase 1-3)
AB001
212Pb-NG001Prostate Cancer
3B Pharmaceuticals
In-LicenseMultiple Solid Tumors
ABA
212Pb-undisclosedMultiple Solid Tumors
ABB
212Pb-undisclosedMultiple Solid Tumors
ABC
212Pb-undisclosedMultiple Solid Tumors
Parabilis Medicines
Multiple TargetsMultiple Solid Tumors
Multiple Targets
In ScreeningMultiple Solid Tumors
A Team of Pioneers and Innovators in RLT
ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy. Born out of groundbreaking research conducted at the University of Oslo and Norway’s Radium Hospital - a research hub with lineage to Marie Curie - ARTBIO’s roots in radiology and radiation therapy run deep. Our scientific founders, Roy Larsen and Øyvind Bruland, invented Xofigo (later acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy. Both collaborated with the F-Prime team and Radforsk to lay the foundation of ARTBIO in 2021.
Our team is composed of multi-disciplinary experts with decades of experience in advancing complex drugs through all stages of clinical development. We are driven by the power of collective thinking, diversity, and a passion to create smarter solutions together. Finally, we take pride in combining creativity and scientific expertise to address challenges. We value inclusion, collaboration, and fostering strong relationships with our team, partners, health care.
- Management Team
- Scientific Founders
- Scientific Advisory Board
- Board of Directors
- Management Team
- Scientific Founders
- Scientific Advisory Board
- Board of Directors
Nick Pullen, PhD
Chief Scientific Officer
Philippe Dasse, PharmD
Chief Technical Officer
Amra Demirovic
Chief Human Resources Officer
Conrad Wüller, MSc
Senior Director, Strategy and Operations
Calvin Lee, MBA
Vice President, Finance
Vicki Jardine, MD, PhD
Vice President, Clinical Development
Lily Bouzelmat, MSc
Vice President, Development Operations
Jordi Vall-llosera Ferran, MSc
Senior Vice President and Global Head of Quality
Victor Paulus, PhD
Head and Senior Vice President, Regulatory Affairs
Daniel Rossetto, MSc
Head & SVP, Supply Chain and External Manufacturing
Tanja Aarvak, PhD
Director, Drug Product Development and Manufacturing
Gjermund Fjeld Olsen, MSc
Director, Generator Development and Manufacturing
Bharat Lagu, PhD
Senior Vice President, Discovery
Phil Ruis, PhD
Director, Partnered Discovery and Business Development
Kate Devlin Rushton
Vice President, Human Resources
Ivana Galetic, PhD
Senior Vice President, Program Management
Sanjay Sharma, MSc, CRadPhr, PhD
Vice President, CMC Operations and Development
Partners
Discovery and Development
Manufacturing
Investors
News and Resources
- Filter By Date
- 2022
- 2023
- 2024
- Press Releases
- Articles
- Publications
- Videos
- Intellectual Property
Join our team
The journey is better together.
Together, we approach challenges head-on and with an open mind. Join our team to help us usher in an entirely new standard of care for cancer patients.
Join us if you are...
passionate about making a difference for cancer patients
a humble achiever
a practical optimist
a consummate learner and un-learner
driven by data and cherish transparency
a compassionate team playerApplying to ARTBIO: Beware of Fraudulent Recruiting Ads and Scams
ARTBIO and other biotech companies have recently noticed an increase in email and social media scams targeting job candidates in our industry. Please note ARTBIO will post any legitimate job openings directly on our website (www.artbio.com) or through our recruitment partner, Lever. If you wish to verify the legitimacy of a job opening, you may contact us through info@artbio.com and someone from our team will respond directly.
Open positions
There are currently no open positions available, please check back soon.